Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

193 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Enrichment of Rare Variants of Hemophagocytic Lymphohistiocytosis Genes in Systemic Juvenile Idiopathic Arthritis.
Marques MC, Rubin D, Shuldiner E, Datta M, Schmitz E, Cruz GG, Patt A, Bennett E, Grom A, Foell D, Gattorno M, Bohnsack J, Yeung RSM, Prahalad S, Mellins E, Anton J, Len CA, Oliveira S, Woo P, Ozen S; INCHARGE Consortium; Deng Z, Ombrello MJ. Marques MC, et al. Among authors: grom a. medRxiv [Preprint]. 2024 Mar 15:2024.03.13.24304215. doi: 10.1101/2024.03.13.24304215. medRxiv. 2024. PMID: 38529491 Free PMC article. Preprint.
IL1RN Variation Influences Both Disease Susceptibility and Response to Recombinant Human Interleukin-1 Receptor Antagonist Therapy in Systemic Juvenile Idiopathic Arthritis.
Arthur VL, Shuldiner E, Remmers EF, Hinks A, Grom AA, Foell D, Martini A, Gattorno M, Özen S, Prahalad S, Zeft AS, Bohnsack JF, Ilowite NT, Mellins ED, Russo R, Len C, Oliveira S, Yeung RSM, Rosenberg AM, Wedderburn LR, Anton J, Haas JP, Rösen-Wolff A, Minden K, Szymanski AM; INCHARGE Consortium; Thomson W, Kastner DL, Woo P, Ombrello MJ. Arthur VL, et al. Among authors: grom aa. Arthritis Rheumatol. 2018 Aug;70(8):1319-1330. doi: 10.1002/art.40498. Epub 2018 Jun 28. Arthritis Rheumatol. 2018. PMID: 29609200 Free PMC article.
Comparative Effectiveness of a Second Tumor Necrosis Factor Inhibitor Versus a Non-Tumor Necrosis Factor Biologic in the Treatment of Patients With Polyarticular-Course Juvenile Idiopathic Arthritis.
Mannion ML, Amin S, Balevic S, Chang ML, Correll CK, Kearsley-Fleet L, Hyrich KL, Beukelman T; Childhood Arthritis and Rheumatology Research Alliance Registry Investigators and the UK Juvenile Idiopathic Arthritis Biologics Register Investigators. Mannion ML, et al. Arthritis Care Res (Hoboken). 2024 Mar 31. doi: 10.1002/acr.25339. Online ahead of print. Arthritis Care Res (Hoboken). 2024. PMID: 38556945
Part 5: Allogeneic HSCT in refractory SJIA with lung disease; recent cases from centers in North America & Europe.
Grom AA, Canna SW, Abu-Arja RF, Sinha R, Peixoto L, Cannizzaro E, Chandrakasan S, Driest K, Marsh R, Neven B, Onel K, Prahalad S, Prockop S, Quartier P, Roth J, Schulert G, Silva JMF, Wall D, Zeilhofer U. Grom AA, et al. Pediatr Rheumatol Online J. 2024 Jan 5;21(Suppl 1):86. doi: 10.1186/s12969-023-00868-x. Pediatr Rheumatol Online J. 2024. PMID: 38183096 Free PMC article.
Atherosclerosis Progression in the APPLE Trial Can Be Predicted in Young People With Juvenile-Onset Systemic Lupus Erythematosus Using a Novel Lipid Metabolomic Signature.
Peng J, Dönnes P, Ardoin SP, Schanberg LE, Lewandowski L; APPLE trial investigators and Childhood Rheumatology Research Alliance (CARRA); Robinson G, Jury EC, Ciurtin C. Peng J, et al. Arthritis Rheumatol. 2024 Mar;76(3):455-468. doi: 10.1002/art.42722. Epub 2023 Dec 19. Arthritis Rheumatol. 2024. PMID: 37786302 Clinical Trial.
193 results